RT Journal Article
T1 Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals
A1 Al-kuraishy, Hayder M.
A1 El-Saber Batiha, Gaber
A1 Faidah, Hani
A1 Al-Gareeb, Ali I.
A1 Saad, Hebatallah M.
A1 Simal Gándara, Jesús
K1 3209 Farmacología
K1 3205.08 Enfermedades Pulmonares
K1 2301 Química analítica
AB Pirfenidone (PFN) is an anti-fbrotic drug with signifcant anti-infammatory property used for treatment of fbrotic conditions such as idiopathic pulmonary fbrosis (IPF). In the coronavirus disease 2019 (Covid-19) era, severe acute respiratorysyndrome 2 (SARS-CoV-2) could initially lead to acute lung injury (ALI) and in severe cases may cause acute respiratorydistress syndrome (ARDS) which is usually resolved with normal lung function. However, some cases of ALI and ARDSare progressed to the more severe critical stage of pulmonary fbrosis commonly named post-Covid-19 pulmonary fbrosiswhich needs an urgent address and proper management. Therefore, the objective of the present study was to highlight thepotential role of PFN in the management of post-Covid-19 pulmonary fbrosis. The precise mechanism of post-Covid-19pulmonary fbrosis is related to the activation of transforming growth factor beta (TGF-β1), which activates the release ofextracellular proteins, fbroblast proliferation, fbroblast migration and myofbroblast conversion. PFN inhibits accumulationand recruitment of infammatory cells, fbroblast proliferation, deposition of extracellular matrix in response to TGFβ1 andother pro-infammatory cytokines. In addition, PFN suppresses furin (TGFβ1 convertase activator) a protein efector involvedin the entry of SARS-CoV-2 and activation of TGFβ1, and thus PFN reduces the pathogenesis of SARS-CoV-2. Besides,PFN modulates signaling pathways such as Wingless/Int (Wnt/β-catenin), Yes-Associated Protein (YAP)/Transcription CoActivator PDZ Binding Motif (TAZ) and Hippo Signaling Pathways that are involved in the pathogenesis of post-Covid-19pulmonary fbrosis. In conclusion, the anti-infammatory and anti-fbrotic properties of PFN may attenuate post-Covid-19pulmonary fbrosis.
PB Inflammopharmacology
SN 09254692
YR 2022
FD 2022-08-31
LK http://hdl.handle.net/11093/4600
UL http://hdl.handle.net/11093/4600
LA eng
NO Inflammopharmacology, 30(6): 2017-2026 (2022)
NO Financiado para publicación en acceso aberto: Universidade de Vigo/CISUG
DS Investigo
RD 15-oct-2024